Business Wire

SEOUL-VIOSYS

2.9.2022 11:56:41 CEST | Business Wire | Press release

Share
Seoul Viosys to Demonstrate the Unparalleled Value of Its Micro-LED at IFA 2022

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a manufacturer of optical semiconductor devices, will present micro-LED based on the laminated structure – which enables high-resolution display – as well as its micro-LED display products at the IFA (Internationale Funkausstellung Berlin) 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220902005087/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Remarkable color mixing technique developed based on Seoul Viosys’s unique technology (Graphic: Business Wire)

The stacked micro-LED developed by Seoul Viosys has a unique and innovative structure in which three chips representing red, green, and blue (R/G/B) are vertically arrayed instead of the usual horizontal array. Its main difference from conventional micro-LEDs is that its R/G/B LED in the stacked structure emit colors as if they constitute a single pixel through perfect color mixing.

Micro-LED produced by Seoul Viosys can achieve deep black color and clear image thanks to the stacked structure. Also, as colors combining R/G/B are emitted externally from inside a pixel, viewers can enjoy clear pictures without distortions from any direction.

The stacked micro-LED to be presented by Seoul Viosys at the exhibition is based on an innovative future technology that can manufacture 4K display screens between 100 and 200 inches. There will be a space where visitors can experience micro-LED in the company’s booth. It will show two micro-LED displays, including a 54-inch high-resolution 0.625mm pitch (P0.625) display and an 81.5-inch 0.9375mm pitch (P0.9375) display. Visitors will be able to enjoy highly immersive clear pictures wherein each pixel comes alive.

Various products representing key production processes of Seoul Viosys’s micro-LED, which have not been unveiled publicly, will also be on display. By exhibiting epitaxial wafers, cabinets, and other products fabricated using high-level transfer technology of moving micro-LED to a display substrate, the company will offer differentiated prices and quality while demonstrating its distinctive values.

In addition, Seoul Viosys will have an exhibition on its display LED techniques supporting its micro-LED technology, such as the molding technique that controls the moiré phenomenon and highlights the details of the black color, the low reflection technique that helps achieve vivid colors and high contrast ratios in the light, and the customized free form-factor design cabinet display that allows easy installation and replacement of microdisplay and change to various sizes.

As micro-LED has to run stably on extremely low power, it is difficult to achieve technological innovation without LED growth technology. Seoul Viosys already owns quantum efficiency enhancement technology for 1㎛-sized micro-LED through joint research with Nobel Laureate Shuji Nakamura, a professor at UC Santa Barbara, the U.S. The company also operates entire processes from the production of a red-green-blue light-emitting substrate to the manufacturing of devices and modules. Notably, WICOP, Seoul Viosys’s original technology, was applied to its micro-LED. WICOP is a key source technology that is necessary for producing micro-LED. It enables the fabrication of micro-scale chips by using no additional parts such as wires and has high reliability due to process simplification.

“By securing WICOP, a source technology for micro-LED and mini-LED, and quantum efficiency enhancement technology, Seoul Viosys is now ready to address any customer requests,” President Hwang Jeong-hwan of Seoul Viosys said. “Our micro-LED will enable the best image quality that viewers have never experienced before, and offer the top-notch solution in the rapidly changing large display market.”

He continued to say, “Seoul Viosys is introducing its products integrated for the purpose of providing a better solution to our customers, comprising LED, molding, and cabinet technologies, and demonstrating its competence,” once again stressing the company’s management principle of ‘no competition with customers.’

Seoul Viosys will introduce its Real One Pixel product that will be presented at the IFA 2022 on its social channels including YouTube (https://www.youtube.com/watch?v=kMJUzwxDqxk).

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Real One Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Real One Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005087/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye